温肾补肺方联合布地奈德治疗慢性阻塞性肺疾病临床研究

Clinical Study of Wenshen Bufei Perscription Combined with Budesonide for Chronic Obstructive Pulmonary Disease

目的:观察温肾补肺方联合布地奈德对慢性阻塞性肺疾病(COPD)的临床治疗效果。方法:将80例COPD患者采用随机对照的方法分为2组各40例。对照组给予布地奈德吸入治疗,治疗组在对照组治疗基础之上给予温肾补肺方进行治疗,观察2组临床治疗效果。结果:对照组总有效率为77.5%,治疗组为95.0%,2组比较,差异有统计学意义(P <0.05)。2组治疗前肺功能指标比较,差异无统计学意义(P> 0.05)。2组治疗后各肺功能指标均较治疗前改善(P <0.05)。治疗后,2组间肺功能指标比较,差异有统计学意义(P <0.05)。2组治疗前呼吸困难评分比较,差异无统计学意义(P> 0.05)。对照组治疗后呼吸困难评分较前无变化(P> 0.05)。治疗组治疗前后呼吸困难评分比较,差异有统计学意义(P <0.05),治疗后2组间比较,差异有统计学意义(P <0.05)。结论:温肾补肺方联合布地奈德治疗COPD可缓解患者的临床症状,改善患者的生活质量。

Objective : To observe the clinical effect of Wenshen Bufei perscription combined with budesonide for chronic obstructive pulmonary disease(COPD). Methods: Divided 80 cases of patients with COPD into two groups randomly, 40 cases in each group. The control group received the inhalation of budesonide for treatment, while the treatment group additionally received Wenshen Bufei prescription based on the treatment of the control group. Observed the clinical effect in the two groups. Results: The total effective rate was 77.5% in the control group and was 95.0% in the treatment group, the difference being significant(P < 0.05). Compared with the indexes of lung function before treatment in the two groups, there was no significance in the difference(P > 0.05). The indexes of lung function in the two groups were improved when compared with those before treatment(P < 0.05). After treatment, compared with the indexes of lung function in the two groups, the difference being significant(P < 0.05). Compared with the scores of dyspnea in the two groups before treatment, there was no significance in the difference(P> 0.05). No significant difference was found in the comparison of the score of dyspnea in the control group before and after treatment(P > 0.05). Compared with the score of dyspnea in the treatment group before and after treatment,the difference being significant(P < 0.05), and compared with the score of dyspnea after treatment between the two groups,the difference being significant(P < 0.05). Conclusion: The therapy of Wenshen Bufei perscription combined with budesonide for COPD can relieve the clinical symptom and improve the quality of life of patients.